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Abstract: Psilocybin is the psychoactive compound of mushrooms in the psilocybe species. Psilocybin
directly affects a number of serotonin receptors, with highest affinity for the serotonin 2A receptor
(5HT-2Ar). Generally, the effects of psilocybin, and its active metabolite psilocin, are well established
and include a range of cognitive, emotional, and perceptual perturbations. Despite the generality of
these effects, there is a high degree of inter-individual variability in subjective psilocybin experiences
that are not well understood. Others have shown brain morphology metrics derived from magnetic
resonance imaging (MRI) can predict individual drug response. Due to high expression of serotonin
2A receptors (5HT-2Ar) in the cingulate cortex, and its prior associations with psilocybin, we
investigate if cortical thickness of this structure predicts the psilocybin experience in healthy adults.
We hypothesized that greater cingulate thickness would predict higher subjective ratings in sub-scales
of the Five-Dimensional Altered State of Consciousness (5D-ASC) with high emotionality in healthy
participants (n = 55) who received oral psilocybin (either low dose: 0.160 mg/kg or high dose:
0.215 mg/kg). After controlling for sex, age, and using false discovery rate (FDR) correction, we
found the rostral anterior cingulate predicted all four emotional sub-scales, whereas the caudal and
posterior cingulate did not. How classic psychedelic compounds induce such large inter-individual
variability in subjective states has been a long-standing question in serotonergic research. These
results extend the traditional set and setting hypothesis of the psychedelic experience to include brain
structure metrics.
Keywords: psilocybin; 5HT2Ar; cingulate; emotion
1. Introduction
In 1953, relatively high concentrations of serotonin (5-hydroxytryptamine or 5-HT) were found
in the brain [1]. Five years later, the Swiss chemist Albert Hofmann isolated psilocybin (4-phosphor
yloxy-N,N-dimethyltryptamine), an indole alkaloid of the tryptamine family, from mushrooms of the
genus Psilocybe used for ceremonial purposes in Mexico. Psilocybin is rapidly dephosphorylated into
the psychoactive metabolite psilocin (4-hydroxy-N,N-dimethyltryptamine) in vitro [2] and in vivo [3].
Pharmacological studies in rats have shown that psilocin primarily binds to 5-HT2A receptors
(5-HT2Ar), with a lower affinity for the 5-HT1Ar and several other 5-HT receptor subtypes [4–6].
Generally, the effects of psilocybin, and its active metabolite psilocin, on human behavior are well
established and include a range of cognitive, emotional, and perceptual perturbations [7–17]. Studies
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using a preferential 5-HT2Ar antagonist have demonstrated psilocybin’s psychoactive effects are
primarily mediated through this receptor [18].
Despite the generality of the psilocybin experience, there is also a high amount of inter and
intra-individual variability in psilocybin subjective responses. Psychedelic research of the 1960s
attributed variability in drug response with the concept of set and setting (for review see [19]).
The set and setting principle posits that the psychedelic experience is highly determined by the
extra-pharmacological parameters of set (personality, preparation, expectation, and intention) and
setting (the physical, social, and cultural environment). Our group and others have postulated
and demonstrated the relative importance of set and setting variables for the subjective response to
psychedelics for over half a century [20–23]. For example, we previously used a pooled analyses
of 261 individuals to test 24 non-pharmacological variables as predictors of the subjective effects of
psilocybin and found, indeed, a variety of set and setting variables are associated with many aspects of
the psilocybin response in healthy volunteers [22]. However, there is a lack of research specifically
assessing biological drivers of the psilocybin experience.
Individual brain morphology measures can be used to predict various pharmacological challenges
and behavior. For example, thicker frontal cortices predict less D-amphetamine induced striatal
dopamine release measured by positron emission tomography (PET) [24–26]. Brain structure
metrics are associated with several aspects of depression such as risk factors, neurobiological
correlates, and pharmacological treatment response [27–30]. Furthermore, individual differences
in the personality dimensions of novelty seeking, harm avoidance, reward dependence, and persistence
also reflect structural variance in specific brain regions [31–33]. Therefore, it is reasonable to presume
individual differences in brain morphologic measures may predict the individual subjective experience
of psilocybin.
In addition to cognitive and perceptual distortions, the effects of psilocybin on emotionality
have been a growing point of interest due to the psycho-therapeutic potential of these compounds.
Therefore, we aimed to identify morphological features that predict the subjective emotional experience
of psilocybin. The Five-Dimensional Altered States of Consciousness Scale (5D-ASC) is a reliable
and validated tool often used to measure the subjective psilocybin experience [34,35]. The 5D-ASC
comprises 11 subscales derived from questions assessing the subjective experiences of an altered
state of consciousness in retrospect [34]. Of the 11 5D-ASC constructs, the four constructs with high
emotionality are: Feeling of Unity, Bliss, Spiritual Experience, and Insightfulness. Psilocybin modulates
activity and functional connectivity throughout the limbic system, which is considered the central
emotional network [13,16,17,36,37]. Because the subjective effects of psilocybin are primarily mediated
by the 5-HT2Ar [18], we chose regions of the limbic system with the highest 5-HT2Ar protein expression,
and identified the cingulate cortex based on prior research (Figure 1A) [38]. We hypothesized that
greater cingulate thickness would predict higher subjective ratings in healthy participants (n = 55)
who received psilocybin (either low dose: 0.160 mg/kg or high dose: 0.215 mg/kg).









Figure 1. Schematic of FreeSurfer brain regions used in analyses. (A) Right hemisphere cingulate cortex
parcellations used in primary analyses. Dark purple = rostral anterior cingulate; medium purple =
caudal anterior cingulate; light purple = posterior cingulate. (B) Red = right hemisphere post central
parcellation used as the control region analysis.
2. Materials and Methods
2.1. Participants
Participants were recruited through advertisements in local universities for two separate groups,
either low dose (0.16 mg/kg: Low) or a high dose (0.215 mg/kg: High). All participants were healthy
based on medical history, physical examination, blood analysis, and electrocardiography, had normal
or corrected-to-normal vision, and were urine tested for drug abuse and pregnancy. The combined
data used for this analysis included 55 participants (33 males, 22 females; mean age 25, SD 3.96 years,
range 20–37 years). Participants received written and oral descriptions of the study procedures as
well as the effects and possible risks of psilocybin administration. All participants provided written
informed-consent statements in accordance with the declaration of Helsinki before participation in the
study. The Swiss Federal Office of Public Health, Bern, Switzerland authorized the use of psilocybin in
humans. Furthermore, the Cantonal Ethics Committee of Zurich approved the study (KEK 2014-0496
12-12-2014; KEK 2012-0303 13-09-12).
2.2. Experimental Design and Psilocybin Administration
In a randomized, double blind, and placebo-controlled study, subjects received either placebo
(maltose) or oral psilocybin (0.16 mg/kg or 0.215mg/kg) in two separate sessions at least 10 days
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apart. These doses reflect the low and high end of the medium dose range commonly used in the
literature [12,39]. Participants had to abstain from smoking for at least 60 min before MRI assessments
and from drinking caffeine during the test day. An anatomical scan was conducted 60 min after drug
administration. The 5D-ASC [34], a self-report questionnaire retrospectively assessing the subjective
experience after drug intake, was completed 360 min after intake. The 5D-ASC comprises 94 items
to be answered on visual analogue scale. Scores have been validated for 11 sub-scales [35], of which
we used four in this study: experience of unity (example item: “I experienced past, present, and
future as a oneness”), spiritual experience (example item: “I experienced a kind of awe”), blissful
state (example item: “I enjoyed boundless pleasure”), and insightfulness (example item: “I gained
clarity into connections that puzzled me before”). All items that comprise these subscales can be found
here [35]. Participant report of psilocybin minus placebo was used to calculate the delta (∆) variables
used in analyses.
2.3. Neuro-Imaging Acquisition
All MR data were acquired on a Philips Achieva 3.0T whole-body scanner (Best, The Netherlands).
Inflatable pillows (Multipad, Pearltec AG, Zurich, Switzerland) were used to increase participant comfort
in the scanner and to reduce motion induced artifacts. High-resolution anatomical images (voxel size, 1 ×
1 × 1 mm) were acquired using a standard T1-weighted three-dimensional (3D) magnetization prepared
rapid gradient echo sequence (MP-RAGE). Each session consisted of a resting state arterial spin labeling
perfusion-weighted scan and several task-related blood-oxygen-level-dependent scans [13,16,17].
2.4. Image Data Processing
T1-weighted images from the placebo session were processed to obtain cortical thickness using
FreeSurfer version 6.0 image analysis suite (surfer.nmr.mgh.harvard.edu/). These processing steps have
been described in detail elsewhere [40–42]. Cortical thickness was defined as the distance between
the white/gray matter boundary to the pial surface. We chose cortical thickness, rather than surface
area or volume, because of previous literature associating this metric with drug response [24–26].
Segmentations were visually inspected to ensure accuracy of automated processes. Regions of interest
were based on high 5HT-2Ar expression in limbic regions (rostral anterior cingulate, caudal anterior
cingulate, and posterior cingulate; Figure 1) [38]. A control region was chosen on lowest 5HT-2Ar
expression in a cortical region (post central; Figure 1B) [38]. Cortical thickness values for the three
areas of the cingulate and the post central gyrus were extracted from the Desikan atlas.
2.5. Statistical Analyses
To assess a difference in the sub-scales between dose groups we ran an analysis of covariance
(ANCOVA), controlling for sex and age. Because there was no difference between groups, for further
analyses we collapsed across dose and used it as a covariate. We ran multivariate linear regressions
controlling for sex, age, control region, and dose with rostral anterior cingulate, caudal anterior
cingulate, and posterior cingulate thickness as predictor variables for all models for the four emotional
sub-scales. The 5D-ASC sub-scale variables were calculated as psilocybinScale – placeboScale =
∆Scale. The Benjamini-Hochberg (false-discovery rate; FDR) procedure was conducted to control for
multiple comparisons and Type 1 error within each hemisphere. Lastly, as a follow up to the significant
associations, we compared the correlated correlation coefficients between the three cingulate regions in
the right hemisphere for each sub-scale to determine if they were significantly different using methods
outlined here [43].
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3. Results
3.1. Dose Comparison
There were no significant differences between the two doses on the behavioral sub-scales (Table 1).
Therefore, for further analyses we collapsed across dose and included dose as a covariate.
Table 1. Comparison between doses on sub-scales.
Low (0.16 mg/kg) High (0.215mg/kg)
p-Value
Construct Mean SE Mean SE
Unity 26 5 33 5 0.495
Spiritual 12 4 16 4 0.975
Bliss 38 6 43 6 0.75
Insight 25 5 36 6 0.516
Max value = 100. Values reported as psilocybin - placebo.
3.2. Cingulate Thickness Predicting Sub-Scales
We found a significant positive association between the right hemisphere rostral anterior cingulate
thickness and all ∆Scales; Feeling of Unity, Bliss, Spiritual Experience, and Insightfulness (Figure 2).
Standardized beta values, SE, p, and FDR corrected p values can be found for all the rostral anterior
cingulate models in Table 2. We found no significant associations with the caudal anterior cingulate or
posterior cingulate cortex thickness and ∆Scales (Table 3).




Figure 2. Partial correlation plots controlling for sex, age, and dose between responses to psilocybin
(Unity, Bliss, Spiritual, and Insight) and estimates of right hemisphere rostral anterior cingulate cortex
(R rACC) thickness with 95% confidence intervals. Scatter plots for non-significant results can be found
in Supplementary Materials. Axes represent normalized values. Response to psilocybin is represented
as the delta value; psilocybin – placebo.
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Table 2. Right Hemisphere Rostral Anterior Cingulate Thickness Predicts the Emotional
Psilocybin Experience.
Sub-Scale
Rostral Anterior Cingulate Cortex (rACC)
β SE p FDR p
Unity
LH 0.295 17.93 0.037 0.114
RH 0.324 17.18 0.027 0.027
Bliss
LH 0.106 25.14 0.465 0.465
RH 0.386 18.95 0.008 0.011
Spiritual
LH 0.266 13.84 0.057 0.114
RH 0.465 * 12.35 0.001 0.002
Insight
LH 0.179 20.26 0.202 0.269
RH 0.572 *# 16.46 0.00002 0.00008
FDR: false discovery rate; LH: left hemisphere; RH right hemisphere; β: standardized regression coefficient; SE:
standard error; * Age < 0.05; # Dose < 0.05.
Table 3. Caudal and posterior cingulate thickness do not predict psilocybin emotional experience.
Sub-Scale
Caudal Cingulate Posterior Cingulate
β SE p β SE p
Unity
LH −0.021 22.383 0.884 0.108 22.289 0.454
RH 0.275 16.976 0.065 0.062 30.219 0.676
Bliss
LH −0.106 25.141 0.465 −0.046 25.287 0.749
RH 0.006 19.852 0.969 0.01 34.181 0.947
Spiritual
LH 0.213 16.749 0.132 0.052 17.144 0.711
RH 0.109 13.39 0.463 −0.028 23.175 0.852
Insight
LH 0.186 24.158 0.186 0.125 24.428 0.371
RH 0.241 18.781 0.099 −0.033 33.242 0.82
FDR: false discovery rate; LH: left hemisphere; RH right hemisphere; β: standardized regression coefficient; SE:
standard error; * Age < 0.05; # Dose < 0.05.
3.3. Comparing Correlated Correlation Coefficients
We found the correlation coefficients between right hemisphere rostral anterior, caudal, and
posterior cingulate for Unity (p = 0.05), Spiritual (p < 0.001), Insight (p < 0.001), and Insight (p < 0.001)
were significantly different using methods outlined here [43].
4. Discussion
This is the first study to evaluate brain morphology as a predictor of the emotional subjective
experience of psilocybin in healthy controls. We focused our analyses on the cingulate cortex based on
high 5-HT2Ar expression levels compared to other limbic regions. We found rostral anterior cingulate
thickness specifically predicted all four sub-scales of Unity, Spiritual Experience, Blissful State, and
Insightfulness, whereas the caudal anterior and posterior cingulate did not. These results point towards
the possibility that morphology metrics such as cortical thickness may reflect differences in brain
substrates that mediate drug effects.
The anterior portion of the cingulate is a unique region of the brain for its connections to both
the limbic system and the more cognitive prefrontal cortex [44]. Our results of rostral, but not other
sub-divisions of the cingulate, predicting emotional experiences aligns well with current anatomical
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knowledge of the cingulate. Briefly, the anterior cingulate has extensive connections with areas known
to be important for emotion, memory, and reward related functions whereas the caudal cingulate
has extensive connections with cognitive and motor-related areas of cortex [41]. Lastly, the posterior
cingulate has connections throughout the neocortex, is crucial component of the default mode network,
and is thought to play a pivotal role in the recall of autobiographical memories [45]. While it was
surprising to us that posterior cingulate thickness did not predict the psilocybin emotional experience
due to the structure’s previous associations with psilocybin [46], our results further highlight the
importance of anterior cingulate in emotional processing. For example, others have found the anterior
cingulate to be involved in emotional and self-processing in healthy controls [47,48], and anterior
cingulate activity changes have been associated with Mindfulness-Based Stress Reduction interventions
in back pain patients with depression [49]. While the amygdala is typically considered the key
limbic structure with a central role in emotion [50], emotional control is considered a “top-down”
regulation process from several areas of frontal cortex [51]. For example, the anterior cingulate cortex
projects to both the amygdala and the prefrontal cortex, which is thought to provide the capacity for
emotional regulation [52]. Taken together, one might speculate that cingulate 5-HT2A activation by
psilocybin/psilocin plays a major role in inducing the profound emotional occurrences often associated
with psilocybin.
There is some evidence suggesting the experience of emotion (i.e., mood and affect) is
predominantly regulated by the right hemisphere [53,54]. Our results indicate right hemisphere
cingulate morphology is a better predictor of psilocybin-induced emotional experiences compared
to the left hemisphere. These results align well with the previous findings from our group and
others that classic psychedelic compounds induce hyperfrontal effects particularly in the right
hemisphere [9,13,55–57]. Right-hemisphere processing is historically described to possess holistic,
gestalt, or integrative characteristics compared to the left hemisphere [58,59]. Specifically, the right
hemisphere is superior in processing emotional affect and affective linguistic characteristics such as
metaphor [53,60]. Because the right hemisphere appears to be involved in emotional processing, perhaps
the right lateralized effects of psilocybin play a role in its reported psychotherapeutic effectiveness
across a wide range of psychiatric disorders [61].
A recent open-label trial using psilocybin for treatment resistant depression found the composite
variable of Unity, Spiritual Experience, and Blissful State along with Insightfulness predicted therapeutic
outcomes [62]. The spiritual experience of psilocybin, along with the persistent increased sense of
well-being and life satisfaction, has been reported to account for sustained reductions in smoking
and drinking behavior and decreased depression and anxiety [39,63–67]. While the underlying
mechanism(s) linking these subjective states with long-term reductions in maladaptive behavior
are unknown, these emotional states reflect common therapeutic goals such as decreasing social
disconnection, negative rumination, and hopelessness [68–72]. Furthermore, it is hypothesized that
the direct 5-HT2Ar agonist properties of psilocybin enhance sensitivity and facilitates emotional
release, which, when combined with psychological support, leads to symptom reduction [73]. If
psilocybin clinical trials continue to demonstrate effective therapeutic properties, discovering individual
biomarkers to help predict which patients are most likely to benefit from these therapies will be
an important line of research [74]. Biomarkers prospectively predicting effective treatment options
could assist in individualized treatment planning, reducing time spent on ineffective treatments,
shortening patient suffering, and reducing the overall cost burden of depression [75]. Our results
suggest neuroimaging may benefit precision medicine approaches of future psychedelic assisted
treatment options.
One limitation of this study is that our design does not allow for a causal inference between brain
morphology and psilocybin subjective states. However, our self-report data does take into account
the participant’s baseline emotional states by using self-report from both psilocybin and placebo
sessions. This is important as it allows us to correlate cingulate thickness with psilocybin-induced
states while functionally controlling for variability in participant baseline mood, excitement, or study
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stress. While including two separate doses of psilocybin is a strength, it is also a limitation that doses
were both in the medium range; thus, we did not detect dose effects. Another strength of this study is
the use of modern neuroimaging methods to extend the set and setting hypothesis to include in vivo
individual brain structure information. However, future research should also include genomic and
epigenetic predictors of individual psilocybin response since allelic variations in monoaminergic genes
have been linked to brain structure and therapeutic response to pharmacological treatments [76–81].
Lastly, because we assessed these relationships with a healthy sample, future research with patient
populations will need to determine if our results prove to be of clinical value.
How classic psychedelic compounds induce such large inter- and intra-variability in subjective
states has been a long-standing question in serotonergic research. Set and setting has been the
prevailing theory for over half a century. Several studies validated this theory and found significant
relationships between non-pharmacological predictors and the psilocybin experience; however, there
are still relatively large proportions of unexplained variance in individual emotional experiences [19,22].
Investigating the relationship between psilocybin modulation and cingulate structure could provide
insight into mechanisms underlying psilocybin’s profound emotional effects and provides a theoretical
framework for brain-based predictors of 5HT2A psychedelic modulation. These results provide the
basis for a potential new unified theory of set, setting, and structure as predictors of the individual
psychedelic experience.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2227-9059/8/2/34/s1.
Author Contributions: F.X.V., K.H.P., and C.R.L. conceived and designed the experiments; K.H.P. performed the
experiments; C.R.L., B.B.B., and C.R. analyzed the data; C.R.L., B.B.B., K.H.P., and F.X.V. wrote the paper. All
authors have read and agreed to the published version of the manuscript.
Funding: This study was financially supported by grants from the Heffter Research Institute and the Swiss
Neuromatrix Foundation.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Twarog, B.M.; Page, I.H. Serotonin content of some mammalian tissues and urine and a method for its
determination. Am. J. Physiol. 1953, 157–161. [CrossRef] [PubMed]
2. Eivindvik, K.; Rasmussen, K.E.; Sund, R.B. Handling of psilocybin and psilocin by everted sacs of rat jejunum
and colon. Acta Pharm. Nord. 1989, 1, 295–302.
3. Hasler, F.; Studerus, E.; Lindner, K.; Ludewig, S.; Vollenweider, F.X. Investigation of serotonin-1A receptor
function in the human psychopharmacology of MDMA. J. Psychopharmacol. 2009, 23, 923–935. [CrossRef]
[PubMed]
4. Passie, T.; Seifert, J.; Schneider, U.; Emrich, H.M. The pharmacology of psilocybin. Addict. Biol. 2002, 7,
357–364. [CrossRef] [PubMed]
5. Mckenna, D.J.; Repke, D.B.; Lo, L.; Peroutka, S.J. Differential interactions of indolealkylamines with
5-hydroxytryptamine receptor subtypes. Neuropharmacology 1990, 29, 193–198. [CrossRef]
6. Vollenweider, F.X.; Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of
mood disorders. Nat. Publ. Gr. 2010, 11, 642–651. [CrossRef] [PubMed]
7. Carter, O.L.; Burr, D.C.; Pettigrew, J.D.; Wallis, G.M.; Hasler, F.; Vollenweider, F.X. Using psilocybin to
investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J.
Cogn. Neurosci. 2005, 17, 1497–1508. [CrossRef]
8. Gouzoulis-Mayfrank, E.; Schreckenberger, M.; Sabri, O.; Hermle, L.; Büll, U.; Sass, H. Neurometabolic Effects
of Psilocybin, (MDE) and d-Methamphetamine in Healthy Volunteers. Neuropsychopharmacology 1999, 20,
565–581. [CrossRef]
9. Griffiths, R.R.; Richards, W. a.; McCann, U.; Jesse, R. Psilocybin can occasion mystical-type experiences
having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl).
2006, 187, 268–283. [CrossRef]
Biomedicines 2020, 8, 34 9 of 12
10. Carbonaro, T.M.; Johnson, M.W.; Hurwitz, E.; Griffiths, R.R. Double-blind comparison of the two
hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Psychopharmacology (Berl). 2018, 235, 521–534. [CrossRef] [PubMed]
11. Griffiths, R.R.; Johnson, M.W.; Richards, W.A.; Richards, B.D.; McCann, U.; Jesse, R. Psilocybin occasioned
mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011,
218, 649–665. [CrossRef] [PubMed]
12. Lewis, C.R.; Preller, K.H.; Kraehenmann, R.; Michels, L.; Stämpfli, P.; Vollenweider, F.X. Two dose investigation
of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 2017, 159, 70–78.
[CrossRef] [PubMed]
13. Pokorny, T.; Preller, K.H.; Kometer, M.; Dziobek, I.; Vollenweider, F.X. Effect of psilocybin on empathy and
moral decision-making. Int. J. Neuropsychopharmacol. 2017, 20, 747–757. [CrossRef] [PubMed]
14. Vollenweider, F.X.; Csomor, P.; Knappe, B.; Geyer, M.; Quednow, B.B. The effects of the preferential 5-HT2A
agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus
interval. Neuropsychopharmacology 2007, 32, 1876–1887. [CrossRef] [PubMed]
15. Kraehenmann, R.; Schmidt, A.; Friston, K.; Preller, K.H.; Seifritz, E.; Vollenweider, F.X. The mixed serotonin
receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin.
2015, 11, 53–60. [CrossRef]
16. Preller, K.H.; Pokorny, T.; Hock, A.; Kraehenmann, R.; Stãmpfli, P.; Seifritz, E.; Scheidegger, M.;
Vollenweider, F.X. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc. Natl.
Acad. Sci. USA 2016, 113, 5119–5124. [CrossRef]
17. Kometer, M.; Schmidt, A.; Bachmann, R.; Studerus, E.; Seifritz, E.; Vollenweider, F.X. Psilocybin biases facial
recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through
different serotonergic subreceptors. Biol. Psychiatry 2012, 72, 898–906. [CrossRef]
18. Hartogsohn, I. Constructing drug effects: A history of set and setting. Drug Sci. Policy Law 2017, 3,
2050324516683325. [CrossRef]
19. Metzner, R.; Litwin, G.H.; Weil, G.M. The Relation of Expectation and Mood to Psilocybin Reactions: A
Questionnaire Study. Psychedelic Rev. 1965, 1, 3–39.
20. Becker, H.S. History, culture and subjective experience: an exploration of the social bases of drug-induced
experiences. J. Health Soc. Behav. 1967, 163–176. [CrossRef]
21. Studerus, E.; Gamma, A.; Kometer, M.; Vollenweider, F.X. Prediction of psilocybin response in healthy
volunteers. PLoS ONE 2012, 7, e30800. [CrossRef]
22. Panton, Y.; Fischer, R. Hallucinogenic Drug-Induced Behavior Under Sensory Attenuation: Prediction of
Response to Psilocybin. Arch. Gen. Psychiatry 1973, 28, 434–438. [CrossRef] [PubMed]
23. Casey, K.F.; Cherkasova, M.V.; Larcher, K.; Evans, A.C.; Baker, G.B.; Dagher, A.; Benkelfat, C.; Leyton, M.
Individual Differences in Frontal Cortical Thickness Correlate with the d-Amphetamine-Induced Striatal
Dopamine Response in Humans. J. Neurosci. 2013, 33, 15285–15294. [CrossRef] [PubMed]
24. Cherkasova, M.V.; Faridi, N.; Casey, K.F.; Larcher, K.; O’Driscoll, G.A.; Hechtman, L.; Joober, R.; Baker, G.B.;
Palmer, J.; Evans, A.C.; et al. Differential Associations between Cortical Thickness and Striatal Dopamine in
Treatment-Naïve Adults with ADHD vs. Healthy Controls. Front. Hum. Neurosci. 2017, 11, 1–14. [CrossRef]
[PubMed]
25. Jaworska, N.; Cox, S.M.; Casey, K.F.; Boileau, I.; Cherkasova, M.; Larcher, K.; Dagher, A.; Benkelfat, C.;
Leyton, M. Is there a relation between novelty seeking, striatal dopamine release and frontal cortical thickness?
PLoS ONE 2017, 12, 1–19. [CrossRef]
26. Chaney, A.; Carballedo, A.; Amico, F.; Fagan, A.; Skokauskas, N.; Meaney, J.; Frodl, T. Effect of childhood
maltreatment on brain structure in adult patients with major depressive disorder and healthy participants. J.
Psychiatry Neurosci. 2014, 39, 50. [CrossRef]
27. Redlich, R.; Almeida, J.R.; Grotegerd, D.; Opel, N.; Kugel, H.; Heindel, W.; Arolt, V.; Phillips, M.L.;
Dannlowski, U. Brain morphometric biomarkers distinguishing unipolar and bipolar depression: A
voxel-based morphometry-pattern classification approach. JAMA Psychiatry 2014, 71, 1222–1230. [CrossRef]
28. Jung, J.; Kang, J.; Won, E.; Nam, K.; Lee, M.S.; Tae, W.S.; Ham, B.J. Impact of lingual gyrus volume
on antidepressant response and neurocognitive functions in Major Depressive Disorder: A voxel-based
morphometry study. J. Affect. Disord. 2014, 169, 179–187. [CrossRef]
Biomedicines 2020, 8, 34 10 of 12
29. Young, R.C.; Kalayam, B.; Nambudiri, D.E.; Kakuma, T.; Alexopoulos, G.S. Brain morphology and response
to nortriptyline in geriatric depression. Am. J. Geriatr. Psychiatry 1999, 7, 147–150. [CrossRef]
30. Schilling, C.; Kühn, S.; Paus, T.; Romanowski, A.; Banaschewski, T.; Barbot, A.; Barker, G.J.; Brühl, R.;
Büchel, C.; Conrod, P.J.; et al. Cortical thickness of superior frontal cortex predicts impulsiveness and
perceptual reasoning in adolescence. Mol. Psychiatry 2013, 36, 4038–4049. [CrossRef]
31. Holmes, A.J.; Hollinshead, M.O.; Roffman, J.L.; Smoller, J.W.; Buckner, R.L. Individual Differences in
Cognitive Control Circuit Anatomy Link Sensation Seeking, Impulsivity, and Substance Use. J. Neurosci.
2016, 36, 4038–4049. [CrossRef] [PubMed]
32. Gardini, S.; Cloninger, C.R.; Venneri, A. Individual differences in personality traits reflect structural variance
in specific brain regions. Brain Res. Bull. 2009, 79, 265–270. [CrossRef] [PubMed]
33. Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.
Pharmacopsychiatry 1998, 31, 80–84. [CrossRef] [PubMed]
34. Studerus, E.; Gamma, A.; Vollenweider, F.X. Psychometric evaluation of the altered states of consciousness
rating scale (OAV). PLoS ONE 2010, 5. [CrossRef]
35. Kraehenmann, R.; Preller, K.H.; Scheidegger, M.; Pokorny, T.; Bosch, O.G.; Seifritz, E.; Vollenweider, F.X.
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy
Volunteers. Biol. Psychiatry 2014, 78, 1–9. [CrossRef]
36. Mayberg, S. Limbic-Cortical Dysregulation: Depression. In The Neuropsychiatry of Limbic and Subcortical
Disorders; American Psychiatric Press: Washington, DC, USA, 1997.
37. Beliveau, V.; Ganz, M.; Feng, L.; Ozenne, B.; Højgaard, L.; Fisher, P.M.; Svarer, C.; Greve, D.N.; Knudsen, G.M.
A high-resolution in vivo atlas of the human brain’s serotonin system. J. Neurosci. 2017, 37, 120–128.
[CrossRef]
38. Griffiths, R.R.; Johnson, M.W.; Carducci, M.A.; Umbricht, A.; Richards, W.A.; Richards, B.D.; Cosimano, M.P.;
Klinedinst, M.A. Psilocybin produces substantial and sustained decreases in depression and anxiety in
patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 2016, 30,
1181–1197. [CrossRef]
39. Cosman, E., Jr.; Fischl, B.; Wells III, W.; Dale, A. Topology Correction for Cortical Surface Models; Massachusetts
Institute of Technology: Cambridge, MA, USA, 1999; pp. 169–170.
40. Fischl, B.; Dale, A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images.
Proc. Natl. Acad. Sci. USA 2000, 97, 11050–11055. [CrossRef]
41. Han, X.; Han, X.; Jovicich, J.; Jovicich, J.; Salat, D.; Salat, D.; van der Kouwe, A.; van der Kouwe, A.; Quinn, B.;
Quinn, B.; et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of
field strength, scanner upgrade and manufacturer. Neuroimage 2006, 32, 180–194. [CrossRef]
42. Meng, X.L.; Rosenthal, R.; Rubin, D.B. Comparing correlated correlation coefficients. Psychol. Bull. 1992, 111,
172. [CrossRef]
43. Stevens, F.L.; Hurley, R.A.; Taber, K.H. Anterior cingulate cortex: Unique role in cognition and emotion. J.
Neuropsychiatry Clin. Neurosci. 2011, 23, 121–125. [CrossRef] [PubMed]
44. Leech, R.; Sharp, D.J. The role of the posterior cingulate cortex in cognition and disease. Brain 2014, 137,
12–32. [CrossRef] [PubMed]
45. Lebedev, A.V.; Lövdén, M.; Rosenthal, G.; Feilding, A.; Nutt, D.J.; Carhart-Harris, R.L. Finding the self by
losing the self: Neural correlates of ego-dissolution under psilocybin. Hum. Brain Mapp. 2015, 36, 3137–3153.
[CrossRef] [PubMed]
46. Smith, R.; Fadok, R.A.; Purcell, M.; Liu, S.; Stonnington, C.; Spetzler, R.F.; Baxter, L.C. Localizing sadness
activation within the subgenual cingulate in individuals: A novel functional MRI paradigm for detecting
individual differences in the neural circuitry underlying depression. Brain Imaging Behav. 2011, 5, 229–239.
[CrossRef]
47. Liotti, M.; Mayberg, H.S.; Brannan, S.K.; McGinnis, S.; Jerabek, P.; Fox, P.T. Differential limbic-cortical
correlates of sadness and anxiety in healthy subjects: Implications for affective disorders. Biol. Psychiatry
2000, 48, 30–42. [CrossRef]
48. Braden, B.B.; Pipe, T.B.; Smith, R.; Glaspy, T.K.; Deatherage, B.R.; Baxter, L.C. Brain and behavior changes
associated with an abbreviated 4-week mindfulness-based stress reduction course in back pain patients.
Brain Behav. 2016, 6, e00443. [CrossRef]
49. LeDoux, J. The amygdala. Curr. Biol. 2007, 17, R868–R874. [CrossRef]
Biomedicines 2020, 8, 34 11 of 12
50. Blair, K.S.; Smith, B.W.; Mitchell, D.G.V.; Morton, J.; Vythilingam, M.; Pessoa, L.; Fridberg, D.; Zametkin, A.;
Sturman, D.; Nelson, E.E.; et al. Modulation of emotion by cognition and cognition by emotion. Neuroimage
2007, 35, 430–440. [CrossRef]
51. Etkin, A.; Egner, T.; Peraza, D.M.; Kandel, E.R.; Hirsch, J. Resolving Emotional Conflict: A Role for the Rostral
Anterior Cingulate Cortex in Modulating Activity in the Amygdala. Neuron 2006, 51, 871–882. [CrossRef]
52. Demaree, H.A.; Everhart, D.E.; Youngstrom, E.A.; Harrison, D.W. Brain lateralization of emotional processing:
Historical roots and a future incorporating “dominance. ” Behav. Cogn. Neurosci. Rev. 2005, 4, 3–20.
[CrossRef]
53. Simon-Thomas, E.R.; Role, K.O.; Knight, R.T. Behavioral and electrophysiological evidence of a right
hemisphere bias for the influence of negative emotion on higher cognition. J. Cogn. Neurosci. 2005, 17,
518–529. [CrossRef] [PubMed]
54. Hermle, L.; Fünfgeld, M.; Oepen, G.; Botsch, H.; Borchardt, D.; Gouzoulis, E.; Fehrenbach, R.A.; Spitzer, M.
Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects:
Experimental psychosis as a tool for psychiatric research. Biol. Psychiatry 1992, 32, 976–991. [CrossRef]
55. Riba, J.; Romero, S.; Grasa, E.; Mena, E.; Carrió, I.; Barbanoj, M.J. Increased frontal and paralimbic activation
following ayahuasca, the pan-amazonian inebriant. Psychopharmacology (Berl). 2006, 186, 93–98. [CrossRef]
[PubMed]
56. Vollenweider, F.X.; Leenders, K.L.; Scharfetter, C.; Maguire, P.; Stadelmann, O.; Angst, J. Positron emission
tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the
psilocybin model of psychosis. Neuropsychopharmacology 1997, 16, 357–372. [CrossRef]
57. Ley, R.G.; Bryden, M.P. Hemispheric differences in processing emotions and faces. Brain Lang. 1979, 7,
127–138. [CrossRef]
58. Bradshaw, J.L.; Nettleton, N.C. The nature of hemispheric specialization in man. Behav. Brain Sci. 1981, 4,
51–63. [CrossRef]
59. Bottini, G.; Corcoran, R.; Sterzi, R.; Paulesu, E.; Schenone, P.; Scarpa, P.; Frackowiak, R.S.J.; Frith, D. The
role of the right hemisphere in the interpretation of figurative aspects of language a positron emission
tomography activation study. Brain 1994, 117, 1241–1253. [CrossRef]
60. Thomas, K.; Malcolm, B.; Lastra, D. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for
Psychiatric Disorders. J. Psychoactive Drugs 2017, 49, 446–455. [CrossRef]
61. Carhart-Harris, R.L.; Bolstridge, M.; Day, C.M.J.; Rucker, J.; Watts, R.; Erritzoe, D.E.; Kaelen, M.; Giribaldi, B.;
Bloomfield, M.; Pilling, S.; et al. Psilocybin with psychological support for treatment-resistant depression:
six-month follow-up. Psychopharmacology (Berl). 2018, 235, 399–408. [CrossRef]
62. Johnson, M.W.; Garcia-Romeu, A.; Cosimano, M.P.; Griffiths, R.R. Pilot study of the 5-HT2AR agonist
psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 2014, 28, 983–992. [CrossRef]
63. Bogenschutz, M.P.; Forcehimes, A.A.; Pommy, J.A.; Wilcox, C.E.; Barbosa, P.; Strassman, R.J.
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. 2015, 29,
289–299. [CrossRef] [PubMed]
64. Ross, S.; Bossis, A.; Guss, J.; Agin-Liebes, G.; Malone, T.; Cohen, B.; Mennenga, S.E.; Belser, A.; Kalliontzi, K.;
Babb, J.; et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and
depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 2016,
30, 1165–1180. [CrossRef] [PubMed]
65. Carhart-Harris, R.L.; Bolstridge, M.; Rucker, J.; Day, C.M.J.; Erritzoe, D.; Kaelen, M.; Bloomfield, M.;
Rickard, J.A.; Forbes, B.; Feilding, A.; et al. Psilocybin with psychological support for treatment-resistant
depression: An open-label feasibility study. The Lancet Psychiatry 2016, 0366, 11–13. [CrossRef]
66. Roseman, L.; Nutt, D.J.; Carhart-Harris, R.L. Quality of acute psychedelic experience predicts therapeutic
efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 2018, 8, 974. [CrossRef]
67. Abramson, L.Y.; Metalsky, G.I.; Alloy, L.B. Hopelessness Depression: A Theory-Based Subtype of Depression.
Psychol. Rev. 1989, 96, 358. [CrossRef]
68. Watkins, E.R. Depressive rumination: Investigating mechanisms to improve cognitive behavioural treatments.
Cogn. Behav. Ther. 2009, 38, 8–14. [CrossRef]
69. Sherry, S.B.; Law, A.; Hewitt, P.L.; Flett, G.L.; Besser, A. Social support as a mediator of the relationship
between perfectionism and depression: A preliminary test of the social disconnection model. Pers. Individ.
Dif. 2008, 45, 339–344. [CrossRef]
Biomedicines 2020, 8, 34 12 of 12
70. Remmers, C.; Michalak, J. Losing your gut feelings. Intuition in depression. Front. Psychol. 2016, 7, 1291.
[CrossRef]
71. Cruwys, T.; Alexander Haslam, S.; Dingle, G.A.; Jetten, J.; Hornsey, M.J.; Desdemona Chong, E.M.; Oei, T.P.S.
Feeling connected again: Interventions that increase social identification reduce depression symptoms in
community and clinical settings. J. Affect. Disord. 2014, 159, 139–146. [CrossRef]
72. Carhart-Harris, R.L.; Goodwin, G.M. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and
Future. Neuropsychopharmacology 2017, 42, 2105–2113. [CrossRef]
73. Strawbridge, R.; Young, A.H.; Cleare, A.J. Biomarkers for depression: Recent insights, current challenges
and future prospects. Neuropsychiatr. Dis. Treat. 2017, 16, 194–209. [CrossRef] [PubMed]
74. McGrath, C.L.; Kelley, M.E.; Holtzheimer, P.E.; Dunlop, B.W.; Craighead, W.E.; Franco, A.R.; Craddock, R.C.;
Mayberg, H.S. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA
Psychiatry 2013, 70, 821–829. [CrossRef]
75. Durston, S.; Fossella, J.A.; Casey, B.J.; Hulshoff Pol, H.E.; Galvan, A.; Schnack, H.G.; Steenhuis, M.P.;
Minderaa, R.B.; Buitelaar, J.K.; Kahn, R.S.; et al. Differential effects of DRD4 and DAT1 genotype on
fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their
unaffected siblings, and controls. Mol. Psychiatry 2005, 10, 678–685. [CrossRef]
76. Shaw, P.; Gornick, M.; Lerch, J.; Addington, A.; Seal, J.; Greenstein, D.; Sharp, W.; Evans, A.; Giedd, J.N.;
Castellanos, F.X.; et al. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure
in attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2007, 64, 921–931. [CrossRef] [PubMed]
77. Fernández-Jaén, A.; López-Martín, S.; Albert, J.; Fernández-Mayoralas, D.M.; Fernández-Perrone, A.L.; de
La Peña, M.J.; Calleja-Pérez, B.; Rodríguez, M.R.; López-Arribas, S.; Muñoz-Jareño, N. Cortical thickness
differences in the prefrontal cortex in children and adolescents with ADHD in relation to dopamine transporter
(DAT1) genotype. Psychiatry Res. -Neuroimaging 2015, 233, 409–417. [CrossRef]
78. Lesch, K.P. Molecular foundation of anxiety disorders. J. Neural Transm. 2001, 108, 717–746. [CrossRef]
79. Müller, J.; Dreisbach, G.; Brocke, B.; Lesch, K.P.; Strobel, A.; Goschke, T. Dopamine and cognitive control: The
influence of spontaneous eyeblink rate, DRD4 exon III polymorphism and gender on flexibility in set-shifting.
Brain Res. 2007, 1131, 155–162. [CrossRef]
80. Lesch, K.P.; Gutknecht, L. Focus on the 5-HT1A receptor: Emerging role of a gene regulatory variant in
psychopathology and pharmacogenetics. Int. J. Neuropsychopharmacol. 2004, 7, 381–385. [CrossRef]
81. Lin, J.Y.; Jiang, M.Y.; Kan, Z.M.; Chu, Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of
antidepressants in the treatment of major depressive disorder: a meta-analysis. J. Affect Disord. 2014, 168,
430–438. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
